clinicaloncologyКлинический случай в онкологииClinical Case in Oncology3034-14773034-4018ОНКОПРАКТИК10.62546/3034-1477-2024-2-4-27-34clinicaloncology-89Research ArticleКЛИНИЧЕСКИЕ СЛУЧАИCASE REPORTSИндивидуальный подход к лечению рака мочевого пузыря у молодых пациентов: клинический случай, трудности и важность коммуникацииPersonalized Approach to Bladder Cancer Treatment in Young Patients: A Clinical Case, Challenges, and the Importance of Communicationhttps://orcid.org/0009-0006-1825-6196МурскихА. Д.MurskikhA. D.

Мурских Алексей ДмитриевичРоссия, 194044, Санкт-Петербург, ул. Чугунная, д. 46

Murskikh Alexei DmitrievichChugunnaya st., 46; St. Petersburg, 194044, Russia

murskih.alex@gmail.comhttps://orcid.org/0000-0002-9787-2117АнохинаЕ. М.AnokhinaE. M.

Екатерина М. АнохинаРоссия, 194044, Санкт-Петербург, ул. Чугунная, д. 46

Ekaterina M. AnokhinaChugunnaya st., 46; St. Petersburg, 194044, Russia

https://orcid.org/0000-0001-9150-1473ЧерновК. Е.ChernovK. E.

Кирилл Е. ЧерновРоссия, 194044, Санкт-Петербург, ул. Чугунная, д. 46

Kirill E. ChernovChugunnaya st., 46; St. Petersburg, 194044, Russia

https://orcid.org/0009-0006-9032-7729ГрушевскийР. О.HrushevskyR. O.

Роман О. ГрушевскийРоссия, 194044, Санкт-Петербург, ул. Чугунная, д. 46

Roman O. HrushevskyChugunnaya st., 46; St. Petersburg, 194044, Russia

https://orcid.org/0000-0003-2767-7153ПоповС. В.PopovS. V.

Сергей В. ПоповРоссия, 194044, Санкт-Петербург, ул. Чугунная, д. 46

Sergey V. PopovChugunnaya st., 46; St. Petersburg, 194044, Russia

СПб ГБУЗ «Клиническая больница Святителя Луки»РоссияSt. Petersburg State Budgetary Healthcare Institution Clinical Hospital of St. LukeRussian Federation202428042025242734Copyright © Мурских А.Д., Анохина Е.М., Чернов К.Е., Грушевский Р.О., Попов С.В., 20252025Мурских А.Д., Анохина Е.М., Чернов К.Е., Грушевский Р.О., Попов С.В.Murskikh A.D., Anokhina E.M., Chernov K.E., Hrushevsky R.O., Popov S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncocase.ru/jour/article/view/89

Рак мочевого пузыря — одна из наиболее распространенных злокачественных опухолей мочевыделительной системы, с ежегодными мировыми показателями заболеваемости более 573 000 случаев и смертностью около 212 000. В последние годы отмечается рост заболеваемости среди молодых взрослых (до 40 лет), что составляет 5–10% всех диагностированных случаев онкологического заболевания. У этой группы болезнь часто протекает агрессивно из-за поздней диагностики, а пациенты сталкиваются с долгосрочными последствиями специализированного лечения, включая нарушение фертильности и снижение качества жизни. В статье представлен клинический случай лечения локализованного рака мочевого пузыря у молодого пациента, обсуждаются трудности диагностики, выбора терапии и долгосрочного наблюдения, подчеркивая необходимость персонализированного подхода.

Bladder cancer is one of the most common malignant tumors of the urinary system, with global annual incidence rates exceeding 573,000 cases and a mortality rate of approximately 212,000. In recent years, there has been an increase in the incidence among young adults (under 40 years of age), accounting for 5–10% of all diagnosed cancer cases. In this group, the disease often progresses aggressively due to late diagnosis, and patients face long-term consequences of specialized treatment, including impaired fertility and reduced quality of life. The article presents a clinical case of treating localized bladder cancer in a young patient, discussing the challenges of diagnosis, treatment selection, and long-term follow-up, while emphasizing the need for a personalized approach.

рак мочевого пузырямолодые пациентыкачество жизниагрессивное течение заболеванияиндивидуальный подходbladder canceryoung patientsquality of lifeaggressive disease coursepersonalized approachReferencesBray F. et al. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries // CA: A Cancer Journal for Clinicians. 2024. Vol. 74, No. 3, Wiley-Blackwell, Apr. 2024. Р. 229–263. https://doi.org/10.3322/caac.21834.Bray F. et al. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries // CA: A Cancer Journal for Clinicians. 2024. Vol. 74, No. 3, Wiley-Blackwell, Apr. 2024. Р. 229–263. https://doi.org/10.3322/caac.21834.Siegel R.L. et al. Cancer Statistics, 2023 // CA: A Cancer Journal for Clinicians. 2023. Vol. 73, No. 1. Р. 17–48. https://doi.org/10.3322/caac.21763.Siegel R.L. et al. Cancer Statistics, 2023 // CA: A Cancer Journal for Clinicians. 2023. Vol. 73, No. 1. Р. 17–48. https://doi.org/10.3322/caac.21763.Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2021 году. Заболеваемость и смертность. М., 2022.Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2021 году. Заболеваемость и смертность. М., 2022.Burger M. et al. Epidemiology and Risk Factors of Urothelial Bladder Cancer // European Urology. 2013. Vol. 63, No. 2. Р. 234–241, https://doi.org/10.1016/j.eururo.2012.07.033.Burger M. et al. Epidemiology and Risk Factors of Urothelial Bladder Cancer // European Urology. 2013. Vol. 63, No. 2. Р. 234–241, https://doi.org/10.1016/j.eururo.2012.07.033.Antoni S. et al. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends // European Urology. Vol. 71, No. 1, Jan. 2017. Р. 96–108. https://doi.org/10.1016/j.eururo.2016.06.010.Antoni S. et al. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends // European Urology. Vol. 71, No. 1, Jan. 2017. Р. 96–108. https://doi.org/10.1016/j.eururo.2016.06.010.Knowles M.A., Carolyn D.Н. Molecular Biology of Bladder Cancer: New Insights into Pathogenesis and Clinical Diversity // Nature Reviews Cancer. Vol. 15, No. 1, Dec. 2014. Р. 25–41. https://doi.org/10.1038/nrc3817.Knowles M.A., Carolyn D.Н. Molecular Biology of Bladder Cancer: New Insights into Pathogenesis and Clinical Diversity // Nature Reviews Cancer. Vol. 15, No. 1, Dec. 2014. Р. 25–41. https://doi.org/10.1038/nrc3817.The Cancer Genome Atlas Research Network. Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma // Nature. Vol. 507, No. 7492, Jan. 2014. Р. 315–322, https://doi.org/10.1038/nature12965.The Cancer Genome Atlas Research Network. Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma // Nature. Vol. 507, No. 7492, Jan. 2014. Р. 315–322, https://doi.org/10.1038/nature12965.Wu Xue-Ru. Urothelial Tumorigenesis: A Tale of Divergent Pathways // Nature Reviews Cancer. Vol. 5, No. 9, Aug. 2005. Р.713–725. https://doi.org/10.1038/nrc1697. Accessed 22 Nov. 2019.Wu Xue-Ru. Urothelial Tumorigenesis: A Tale of Divergent Pathways // Nature Reviews Cancer. Vol. 5, No. 9, Aug. 2005. Р.713–725. https://doi.org/10.1038/nrc1697. Accessed 22 Nov. 2019.Jones P.A., Laird P.W. Cancer-Epigenetics Comes of Age // Nature Genetics. Vol. 21, No. 2, Feb. 1999. Р. 163–167. https://doi.org/10.1038/5947.Jones P.A., Laird P.W. Cancer-Epigenetics Comes of Age // Nature Genetics. Vol. 21, No. 2, Feb. 1999. Р. 163–167. https://doi.org/10.1038/5947.Choi W. et al. Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy // Cancer Cell. Vol. 25, No. 2, Feb. 2014. Р. 152–165. https://doi.org/10.1016/j.ccr.2014.01.009.Choi W. et al. Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy // Cancer Cell. Vol. 25, No. 2, Feb. 2014. Р. 152–165. https://doi.org/10.1016/j.ccr.2014.01.009.Alhubaishy B. et al. Primary Urothelial Bladder Cancer in a Young Patient: A Case Report and Review of the Literature // Cureus. 2021. Vol. 13, No. 6. https://doi.org/10.7759/cureus.15864. Accessed 19 Mar. 2022.Alhubaishy B. et al. Primary Urothelial Bladder Cancer in a Young Patient: A Case Report and Review of the Literature // Cureus. 2021. Vol. 13, No. 6. https://doi.org/10.7759/cureus.15864. Accessed 19 Mar. 2022.Khan R. et al. Bladder Cancer in a Young Patient: Undiscovered Risk Factors // Oncology Letters. Vol. 11, No. 5, Mar. 2016. Р. 3202–3204. https://doi.org/10.3892/ol.2016.4355. Accessed 23 Jan. 2020.Khan R. et al. Bladder Cancer in a Young Patient: Undiscovered Risk Factors // Oncology Letters. Vol. 11, No. 5, Mar. 2016. Р. 3202–3204. https://doi.org/10.3892/ol.2016.4355. Accessed 23 Jan. 2020.Singh P. et al. Comparative Analysis of Clinicopathologic Characteristics and Outcomes of Urothelial Bladder Cancer between Young and Older Adults — Experience from a Tertiary Care Center // Indian Journal of Surgical Oncology. Vol. 15, No. 3, May 2024. Р. 563–71. https://doi.org/10.1007/s13193-024-01950-w. Accessed 3 Mar. 2025.Singh P. et al. Comparative Analysis of Clinicopathologic Characteristics and Outcomes of Urothelial Bladder Cancer between Young and Older Adults — Experience from a Tertiary Care Center // Indian Journal of Surgical Oncology. Vol. 15, No. 3, May 2024. Р. 563–71. https://doi.org/10.1007/s13193-024-01950-w. Accessed 3 Mar. 2025.Rouprêt M. et al. Microsatellite Instability as Predictor of Survival in Patients with Invasive Upper Urinary Tract Transitional Cell Carcinoma // Urology. 2005. Vol. 65, No. 6, Elsevier BV. Р. 1233–1237. https://doi.org/10.1016/j.urology.2005.01.019. Accessed 23 Jan. 2024.Rouprêt M. et al. Microsatellite Instability as Predictor of Survival in Patients with Invasive Upper Urinary Tract Transitional Cell Carcinoma // Urology. 2005. Vol. 65, No. 6, Elsevier BV. Р. 1233–1237. https://doi.org/10.1016/j.urology.2005.01.019. Accessed 23 Jan. 2024.Nassour A.-J. et al. Relative Risk of Bladder and Kidney Cancer in Lynch Syndrome: Systematic Review and Meta-Analysis // Cancers. 2023. Vol. 15, No. 2. Р. 506. https://doi.org/10.3390/cancers15020506.Nassour A.-J. et al. Relative Risk of Bladder and Kidney Cancer in Lynch Syndrome: Systematic Review and Meta-Analysis // Cancers. 2023. Vol. 15, No. 2. Р. 506. https://doi.org/10.3390/cancers15020506.Leoni Ch. et al. Prevalence of Bladder Cancer in Costello Syndrome: New Insights to Drive Clinical Decision‐Making // Clinical Genetics. Vol. 101, No. 4, 17 Feb. 2022. Р. 454–458. https://doi.org/10.1111/cge.14111. Accessed 24 Mar. 2025.Leoni Ch. et al. Prevalence of Bladder Cancer in Costello Syndrome: New Insights to Drive Clinical Decision‐Making // Clinical Genetics. Vol. 101, No. 4, 17 Feb. 2022. Р. 454–458. https://doi.org/10.1111/cge.14111. Accessed 24 Mar. 2025.Andreou A. et al. Early-Onset Low-Grade Papillary Carcinoma of the Bladder Associated with Apert Syndrome and a Germline FGFR2 Mutation (Pro253Arg) // American Journal of Medical Genetics. Part A. 2026. Vol. 140, No. 20. Р. 2245–2247. pubmed.ncbi.nlm.nih.gov/16969861/. https://doi.org/10.1002/ajmg.a.31430. Accessed 10 Mar. 2022.Andreou A. et al. Early-Onset Low-Grade Papillary Carcinoma of the Bladder Associated with Apert Syndrome and a Germline FGFR2 Mutation (Pro253Arg) // American Journal of Medical Genetics. Part A. 2026. Vol. 140, No. 20. Р. 2245–2247. pubmed.ncbi.nlm.nih.gov/16969861/. https://doi.org/10.1002/ajmg.a.31430. Accessed 10 Mar. 2022.Elshabrawy A. et al. Correlates of Refusal of Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer // Urologic Oncology Seminars and Original Investigations. 2021. Vol. 39, No. 4, 9 Jan. Р. 236.e9–236.e20. https://doi.org/10.1016/j.urolonc.2020.11.023. Accessed 24 Mar. 2025.Elshabrawy A. et al. Correlates of Refusal of Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer // Urologic Oncology Seminars and Original Investigations. 2021. Vol. 39, No. 4, 9 Jan. Р. 236.e9–236.e20. https://doi.org/10.1016/j.urolonc.2020.11.023. Accessed 24 Mar. 2025.Vrijland W.W. et al. Abdominal Adhesions: Intestinal Obstruction, Pain, and Infertility. 2003. Vol. 17, No. 7, 14. Р. 1017–1022. https://doi.org/10.1007/s00464-002-9208-9. Accessed 4 June 2023.Vrijland W.W. et al. Abdominal Adhesions: Intestinal Obstruction, Pain, and Infertility. 2003. Vol. 17, No. 7, 14. Р. 1017–1022. https://doi.org/10.1007/s00464-002-9208-9. Accessed 4 June 2023.Holmsten K. et al. Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week versus Four-Week Regimen // Bladder Cancer. 2021. Vol. 8, No. 1, 24 Dec. Р. 71–80. https://doi.org/10.3233/blc-211556. Accessed 27 Dec. 2024.Holmsten K. et al. Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week versus Four-Week Regimen // Bladder Cancer. 2021. Vol. 8, No. 1, 24 Dec. Р. 71–80. https://doi.org/10.3233/blc-211556. Accessed 27 Dec. 2024.Bajorin D.F. et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma // The New England Journal of Medicine. 2021. Vol. 384, No. 22, 3. Р. 2102–2114, pubmed.ncbi.nlm.nih.gov/34077643/, https://doi.org/10.1056/NEJMoa2034442.Bajorin D.F. et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma // The New England Journal of Medicine. 2021. Vol. 384, No. 22, 3. Р. 2102–2114, pubmed.ncbi.nlm.nih.gov/34077643/, https://doi.org/10.1056/NEJMoa2034442.Levinson W. Physician-Patient Communicationthe Relationship with Malpractice Claims among Primary Care Physicians and Surgeons // JAMA: The Journal of the American Medical Association. 1997. Vol. 277, No. 7, 19 Feb. Р. 553. https://doi.org/10.1001/jama.1997.03540310051034.Levinson W. Physician-Patient Communicationthe Relationship with Malpractice Claims among Primary Care Physicians and Surgeons // JAMA: The Journal of the American Medical Association. 1997. Vol. 277, No. 7, 19 Feb. Р. 553. https://doi.org/10.1001/jama.1997.03540310051034.

The authors declare that there are no conflicts of interest present.